Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer

Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC) treatment is still challenging, and immunotherapy is a potential approach in this tumor subtype. Cetuximab is an IgG1 monoclonal antibody (mAb) directed against Epidermic Growth Factor Receptor (EGFR), a protein overexpressed in a subgroup of TNBC patients and as...

Full description

Bibliographic Details
Main Authors: Estefanía Paula Juliá, José Mordoh, Estrella Mariel Levy
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cells
Subjects:
NK cells
dendritic cells
ADCC
Cetuximab
triple negative breast cancer
Online Access:https://www.mdpi.com/2073-4409/9/7/1573

Internet

https://www.mdpi.com/2073-4409/9/7/1573

Similar Items